Probability of Success in BE studies [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2024-05-03 16:15 (357 d 14:34 ago) – Posting: # 23979
Views: 3,165

Hi Achievwin,

❝ Recently I was asked to give Probability of success for a proposed BE study, My thinking is Target study power (usually 80%) is POS with additional correction factor due to the variability during study conduct applied to this target power, is my understanding correct?

Not sure whether I understand you correctly. POS is a Bayesian concept, where you need some prior information. Let’s start with a conventional sample size estimation based purely on assumptions.

library(PowerTOST)
CV     <- 0.25
theta0 <- 0.95
target <- 0.80
sampleN.TOST(CV = CV, theta0 = theta0, design = "2x2", targetpower = target, details = FALSE)

+++++++++++ Equivalence test - TOST +++++++++++
            Sample size estimation
-----------------------------------------------
Study design: 2x2 crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.8
BE margins = 0.8 ... 1.25
True ratio = 0.95,  CV = 0.25

Sample size (total)
 n     power
28   0.807439

Say, you obtained the CV and T/R-ratio in another study with 24 subjects. Based on that, you can take the uncertainty of the CV (#1), of the T/R-ratio (#2), or both (#3) into account.

m <- 24 # sample size of prior study

  1. expsampleN.TOST(CV = CV, theta0 = theta0, design = "2x2", targetpower = target,
                    prior.parm = list(m = m, design = "2x2"), prior.type = "CV", details = FALSE)

    ++++++++++++ Equivalence test - TOST ++++++++++++
           Sample size est. with uncertain CV
    -------------------------------------------------
    Study design:  2x2 crossover
    log-transformed data (multiplicative model)

    alpha = 0.05, target power = 0.8
    BE margins = 0.8 ... 1.25
    Ratio = 0.95
    CV = 0.25 with 22 df

    Sample size (ntotal)
     n   exp. power
    32   0.822645

  2. expsampleN.TOST(CV = CV, theta0 = theta0, design = "2x2", targetpower = target,
                    prior.parm = list(m = m, design = "2x2"), prior.type = "theta0", details = FALSE)

    ++++++++++++ Equivalence test - TOST ++++++++++++
         Sample size est. with uncertain theta0
    -------------------------------------------------
    Study design:  2x2 crossover
    log-transformed data (multiplicative model)

    alpha = 0.05, target power = 0.8
    BE margins = 0.8 ... 1.25
    Ratio = 0.95
    CV = 0.25

    Sample size (ntotal)
     n   exp. power
    44   0.810063

  3. expsampleN.TOST(CV = CV, theta0 = theta0, design = "2x2", targetpower = target,
                    prior.parm = list(m = m, design = "2x2"), prior.type = "both", details = FALSE)

    ++++++++++++ Equivalence test - TOST ++++++++++++
      Sample size est. with uncertain CV and theta0
    -------------------------------------------------
    Study design:  2x2 crossover
    log-transformed data (multiplicative model)

    alpha = 0.05, target power = 0.8
    BE margins = 0.8 ... 1.25
    Ratio = 0.95 with 22 df
    CV = 0.25 with 22 df

    Sample size (ntotal)
     n   exp. power
    48   0.801190
As usual, the T/R-ratio is the killer.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
25 visitors (0 registered, 25 guests [including 7 identified bots]).
Forum time: 06:49 CEST (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5